Table 3.
Correlations between nuclear RKIP expression and the patients’ clinicopathological characteristics
| Clinico-pathological characteristics | Patients (n=421) | RKIP expression H-Score quartile | p value | |||
|---|---|---|---|---|---|---|
|
| ||||||
| 1 (n=107) | 2 (n=104) | 3 (n=106) | 4 (n=104) | |||
| Age (≤50/>50 years) | 115/306 | 25/82 | 31/73 | 33/73 | 26/78 | 0.736 |
| Size (≤20/21-50/>50 mm) | 240/168/11 m2 | 53/51/3 | 52/48/2 m2 | 59/44/3 | 76/25/3 | 0.002 |
| Grade (I/II/III) | 84/180/155 m2 | 11/34/61 m1 | 15/50/39 | 21/54/31 | 37/42/24 m1 | <0.001 (7.98 × 10-5) |
| Nodal status (negative/positive) | 233/182 m6 | 59/47 m1 | 54/49 m1 | 53/52 m1 | 67/34 m3 | 0.101 |
| Oestrogen receptor status (ER-/ER+) | 128/289 m4 | 53/52 m2 | 34/69 m1 | 23/83 | 18/85 m1 | <0.001 (4.68 × 10-5) |
| Progesterone receptor status (PR-/PR+) | 208/206 m7 | 73/32 m2 | 49/54 m1 | 45/59 m2 | 41/61 m2 | <0.001 (2.51 × 10-5) |
| HER2 (HER2-/HER2+) | 348/68 m5 | 79/26 m2 | 82/21 m1 | 93/12 m1 | 94/9 m1 | <0.001 (4.40 × 10-5) |
| Ki67 (≤15/>15) | 310/102 m9 | 68/37 m2 | 74/30 | 84/20 m2 | 84/15 m5 | <0.001 (2.50 × 10-4) |
| TUNEL (≤0.33/>0.33) | 229/174 m18 | 63/40 m4 | 58/45 m1 | 58/44 m4 | 50/45 m9 | 0.262 |
| Necrosis (absent/positive) | 192/217 m12 | 41/65 m1 | 39/60 m5 | 46/57 m3 | 66/35 m3 | <0.001 (2.58 × 10-4) |
| Chemotherapy (no/yes) | 247/172 m2 | 53/53 m1 | 48/55 m1 | 65/41 | 81/23 | <0.001 (5.25 × 10-6) |
| Radiotherapy (no/yes) | 237/182 m2 | 69/37 m1 | 50/53 m1 | 63/43 | 55/49 | 0.080 |
| Endocrine therapy (no/yes) | 97/317 m7 | 37/69 m1 | 21/81 m2 | 21/82 m3 | 18/85 m1 | 0.013 |
| DFS (months) | n=104 m3 | n=98 m6 | n=100 m6 | n=96 m8 | Overall 0.074 | |
| Mean (95% CI) | 82.4 (76.3-88.5) | 89.7 (83.4-96.0) | 88.7 (83.0-94.4) | 96.0 (90.4-101.6) | Quartile 1 vs 4 (p=0.01) | |
m (number of patients) denotes missing cases.